- Both block DHT at the androgen receptor in the scalp, working downstream of finasteride and dutasteride.
- Pyrilutamide has human clinical trial data. RU-58841 does not, only old animal studies and community reports.
- RU-58841 is the older option with the harder-hitting reputation, typically supplied at 5%. Pyrilutamide is newer, far more potent per molecule, and supplied at 0.5%.
- Neither is a licensed medicine. Everything here is for research use only.
The short answer
RU-58841 and pyrilutamide (research code KX-826) are the two topical antiandrogens the hair loss research community reaches for most. They do the same job in the same place, but they arrived from very different places: RU-58841 is a 1980s compound with a long, informal track record and no trials, while pyrilutamide is a modern drug candidate with real clinical data but a shorter history. If you want the longest-standing option and the harder hitter, that is RU-58841. If you want the one with human evidence behind it and a gentler reputation, that is pyrilutamide.
How they both work
Both are topical androgen receptor (AR) antagonists. They sit on the androgen receptor inside the hair follicle and compete with dihydrotestosterone (DHT) for that binding site. If DHT cannot dock, it cannot drive the follicle miniaturisation that produces pattern hair loss.
This is a different point of attack from finasteride and dutasteride. Those reduce how much DHT your body makes systemically. RU-58841 and pyrilutamide leave DHT levels alone and simply block its effect locally, at the scalp. In theory that means the action stays where you put it, which is the whole appeal of a topical antiandrogen. In practice, how well that holds up depends on the compound, the concentration, and the carrier it is dissolved in.
The evidence gap
This is the single biggest difference between them, and most comparisons skip over it.
RU-58841: no human trials
RU-58841 was developed by Roussel-Uclaf in the 1980s and studied for acne, hirsutism and hair loss. Development was discontinued and it never completed human clinical trials. What exists is decades-old animal work, including a controlled study in stump-tailed macaques that showed regrowth, plus a very large body of anecdotal reports from people who have used it for years. That community record is genuinely useful signal, but it is not the same as controlled human data, and RU-58841’s safety profile in humans has never been formally established.
Pyrilutamide: actual clinical data
Pyrilutamide was designed from the start as a hair loss drug by Kintor Pharmaceutical. In March 2026 Kintor reported that KX-826 hit its Phase 3 primary endpoint in a 666-patient, 24-week, vehicle-controlled trial in China: about +15.3 hairs/cm2 from baseline at the 1.0% dose, roughly +10.65 hairs/cm2 over placebo (p<0.0001), with no drug-related serious adverse events reported. That is a real result. The caveats are equally real, though: it is company-reported top-line data, the trial was run entirely in China, and Kintor has faced repeated credibility questions from independent researchers. Promising signal, not a closed case.
Potency: pyrilutamide binds harder
On paper pyrilutamide is the more potent molecule. In binding assays its IC50 is around 0.28 nM, dramatically lower (stronger) than other topical AR antagonists like clascoterone. RU-58841 has less formal binding data published, but is generally considered less potent per molecule, which is part of why it is used at a much higher concentration (5% versus pyrilutamide’s 0.5%).
Potency on a lab bench is not the same as results on a scalp, though. DHT itself binds the receptor very tightly, so a topical has to reach a high enough local concentration to actually outcompete it. That is why the carrier and concentration matter as much as the raw binding number, and why the community’s real-world read is more nuanced than the assay data alone.
In practice: tolerability and reputation
The community consensus, across years of use, tends to land in the same place: RU-58841 is the harder-hitting, more irritation-prone option, and pyrilutamide is the cleaner, better-tolerated one. RU at 5% is more likely to cause scalp irritation, and because it is a stronger overall antiandrogen dose there is more discussion around systemic absorption at higher amounts. Pyrilutamide, used at a fraction of the concentration and with very low reported transdermal absorption, is more often described as side-effect-free by long-term users, though some report results plateauing around the six-month mark.
None of that is a substitute for controlled long-term safety data, which neither compound has in full. It is the honest read of what people report, not a promise of how any given sample will behave.
Side by side
| RU-58841 | Pyrilutamide (KX-826) | |
|---|---|---|
| Mechanism | Topical AR antagonist | Topical AR antagonist |
| Human trials | None completed | Phase 3 (China, 666 patients) |
| Typical concentration | 5% | 0.5% |
| Developed by | Roussel-Uclaf, 1980s | Kintor Pharmaceutical |
| Binding potency | Less formal data | Very high (IC50 ~0.28 nM) |
| Track record | 20+ years community use | Newer, trial-backed |
| Reputation | Harder-hitting, more irritation | Cleaner, better tolerated |
| Regulatory status | Never approved | Not approved outside China trials |
So which one comes out ahead?
There is no universal answer, and any source offering one is selling something. The comparison comes down to which kind of evidence gets weighted more heavily:
- Longest track record and the harder-hitting reputation, at the cost of zero human trials: RU-58841.
- Actual human clinical data and a gentler profile, evidence over anecdote: pyrilutamide.
One honest note on the pairing: they share the same mechanism (androgen receptor blockade), so combining them is not obviously additive the way pairing two different pathways would be: a live debate in the research community, not a claim about synergy.
The honest caveats
Neither RU-58841 nor pyrilutamide is a licensed medicine, and Norwood Labs makes no medical or treatment claims about either. We sell them strictly as reference materials for laboratory research use. RU-58841 has never passed human trials and its human safety profile is not established. Pyrilutamide’s clinical data is early, company-reported, and China-only. We do not give dosing advice. Every batch we sell ships with an independent Certificate of Analysis so you can verify what you actually received, which, given how often these compounds are underdosed or mislabelled, is the part that matters most.